Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07455812) titled 'A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause' on March 3.
Study Type: Observational
Primary Sponsor: Astellas Pharma Europe Ltd.
Condition:
Hot Flashes
Intervention:
Drug: Fezolinetant
Recruitment Status: Not recruiting
Date of First Enrollment: October 29, 2024
Target Sample Size: 105
Countries of Recruitment:
Germany
To know more, visit https://clinicaltrials.gov/study/NCT07455812
Published by HT Digital Content Services with permission from Health Daily Digest....